This trial is testing if a lower dose of Decitabine and venetoclax can kill cancer cells in people with myeloid malignancies while causing less damage to normal cells.
- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
1 Primary · 7 Secondary · Reporting Duration: 12 months
Side Effects for
1 Treatment Group
1 of 1
33 Total Participants · 1 Treatment Group
Primary Treatment: Decitabine · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What potential risks are associated with Decitabine treatment?
"Our team assesses that Decitabine possesses an adequate degree of safety, as evidenced by its rating of 2. This implies there is some research indicating the drug's security but no studies demonstrating its efficacy in treating a condition." - Anonymous Online Contributor
Are there any vacancies for this clinical research initiative?
"The clinicaltrials.gov database confirms that this trial, which was first advertised on March 23rd 2022 is actively recruiting for participants. This information was last updated on July 22nd the same year." - Anonymous Online Contributor
What is the participant capacity for this experiment?
"Indeed, the data hosted on clinicaltrials.gov shows that this medical study is presently enrolling individuals. This trial was initially posted on March 23rd 2022 and has since been modified as recently as July 22nd 2022 - 33 patients are sought from a single site." - Anonymous Online Contributor